Pathos Expands Pipeline With Worldwide License of Phase 2-ready Program, a Brain-penetrant, PRMT5 Inhibitor

Chicago – Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform drug development, announced today the world-wide license of PRT811, a potent, selective, and orally bioavailable brain penetrant SAM-competitive PRMT5 inhibitor from Prelude Therapeutics. PRT811 (renamed P-500) was developed by Prelude Therapeutics and completed a Phase 1 trial in March 2023.